Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America’s top infectious diseases expert said the study showed the medication has “clear-cut” benefits.
The full results of this study conducted by the National Institute of Allergy and Infectious Diseases (NIAID), a US government agency, have been published by the leading medical journal, the New England Journal of Medicine.
The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, and Europe is considering following suit.
The study found that compared with placebo, in daily clinical trials conducted in 10 countries / regions, compared with placebo, intravenous injection of 10 days of remdesivir can accelerate the recovery of hospitalized COVID-19 patients.
NIAID director Anthony Fauci became the trusted face of the US government in the coronavirus pandemic on April 29. He said that preliminary evidence showed that remdesivir had a clear and positive effect on reducing recovery time.
The National Institutes of Health is part of the National Institutes of Health, and the organization said in a statement published online on Friday that the researchers found that “remdesivir is most beneficial to patients with severe hospitalization who need supplemental oxygen.”
But the author of the trial wrote that this drug does not prevent all deaths.
They said: “Despite the use of remdesivir , the mortality rate is very high. Obviously, treatment with antiviral drugs is not enough.”
In the experimental group, approximately 7.1% of patients receiving remdesivir died within 14 days, compared with 11.9% in the placebo group.
However, the result is just below the statistical reliability threshold, which means that the result may be accidental, not the ability of the drug.